Cynosure Group LLC Sells 144 Shares of Humana Inc. (NYSE:HUM)

Cynosure Group LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 10.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,180 shares of the insurance provider’s stock after selling 144 shares during the period. Cynosure Group LLC’s holdings in Humana were worth $299,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares in the last quarter. State Street Corp lifted its position in Humana by 1.0% in the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. Pzena Investment Management LLC boosted its stake in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Geode Capital Management LLC increased its holdings in Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after buying an additional 63,562 shares during the period. Finally, Norges Bank acquired a new position in shares of Humana in the 4th quarter valued at $416,202,000. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 0.4 %

Shares of HUM opened at $264.67 on Friday. The stock’s fifty day simple moving average is $268.40 and its 200-day simple moving average is $272.56. The firm has a market capitalization of $31.94 billion, a PE ratio of 26.60, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Truist Financial increased their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Finally, Barclays upped their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Eighteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $280.17.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.